PRODUCTS & SERVICES
Deputy Prime Minister and Minister of Investment, Regional Development and Informatization of the Slovak Republic, Veronika Remisova, and her team visited our company last week.
Firstly, our team proudly presented the latest findings of our retrospective clinical validation of breast cancer. We were thrilled about the discussion which followed the presentation.
The mission of MultiplexDX company, to develop and bring revolutionary technologies to the market of personalized molecular diagnostics, resonated in the conversation with the Minister. We discussed several possibilities for prospective clinical validation, including the opportunity for the involvement of Slovak patients with breast cancer.
We were honored to have another distinguished guest at MultiplexDX who understands the importance of creating innovative solutions for our country with high scalability and global ambitions.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.